Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Evaluation of SofWave Sofware-Guided Energy Delivery for Lower Face and Neck Rejuvenation

NCT07723664 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2026-07-20
Last updated
2026-07-27

Condition(s) studied

Facial WrinklesJawline ContourSkin Laxity

Investigational drug(s) / intervention(s)

SofWave

SofWave: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues

Study summary

Non-randomized single-arm prospective clinical study.

Eligibility

Sex
ALL
Min age
40 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Healthy female and male subjects between the ages 40-55. 2. Non-Smoker. 3. Fitzpatrick skin type I-VI. 4. Desire to lift facial lax skin, neck and/or submental and/or improve facial wrinkles appearance. 5. Presence of mild to moderate laxity in the lower face and submental area. 6. Able and willing to comply with all visits, treatments and evaluation schedules and requirements. 7. Able to understand and provide written Informed Consent. 8. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment. 9. Subject agrees not to undergo any other facial cosmetic treatment for a period of 3 months following last SofWave treatment. 10. Stable weight over the last 12 weeks and throughout the duration of the study. 11. Subjects agree to adhere to safe sun practices and daily use of broad-spectrum sunscreen SPF 30+. 12. Male subjects with facial hair in the treatment area are willing to trim or shave as needed to allow consistent standardized photography. \- Exclusion Criteria: 1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding. 2. Presence of any active systemic or local infections. 3. Open wounds or lesions within the intended to treat area. 4. Tattoo or former tattoo at or near treatment area. 5. Presence of active local skin disease that may alter wound healing. 6. Uncontrolled diabetes mellitus. 7. Skin cancer in the area to be treated. History of any other non-melanoma skin cancers in the past 5 years within the treatment area (head and neck). 8. Severe solar elastosis. 9. History of smoking in the past 10 years. 10. History of chronic drug or alcohol abuse. 11. Excessive subcutaneous fat on the cheeks. 12. Significant scarring in the area to be treated or history of keloids. 13. Severe or cystic facial acne, and/or Accutane use during the past 6 months. 14. Pacemakers and electronic device implants in the treated area. 15. Presence of a metal stent or implant in the facial area (dental implants and/or braces are not excluded). 16. Inability to understand the protocol or to provide a signed informed consent. 17. History of cosmetic treatments in the area to be treated including: * Chemical peels, microneedling, dermabrasion, energy-based devices, or laser treatments in the past 6 months * Injectable filler treatments in the past 6 months * Injectable neuromodulator treatment in the past 4 months 18. Cosmetic surgical procedures in the treatment area, including but not limited to facelift in the past 12 months. 19. Taking anti-platelet or anti-coagulant within the past 2 weeks. 20. Ongoing use of psychiatric medication; taking psychiatric drugs within the past 2 weeks. 21. As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study. \-

Primary outcome measure(s)

  • Evaluate the clinical efficacy of the treatment for lower face and upper neck rejuvenation — 12 weeks post treatment follow-up visit
    Rate of the Improvement in the appearance of lower face and upper neck rejuvenation following SofWave treatment based on Global Aesthetic Improvement Scale (-1=worse, 0=no change, 1=improved, 2=marked improvement, 3=very much improved)
  • Lower face and upper neck rejuvenation — 12 weeks post treatment follow-up visit
    Evaluate the clinical efficacy of the treatment for lower face and upper neck rejuvenation, as assessed by the study physician using Physician Global Aesthetic Improvement Scale (GAIS; (-1=worse, 0=no change, 1=improved, 2=marked improvement, 3=very much improved)) at 12 weeks follow-up visit.

Trial sites (1)

FacilityCityRegionStatus
Dermatology & Laser Surgery Center Houston Texas
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07723664 on ClinicalTrials.gov ↗ ← All trials in the USA